latest news stock values companies glp-1 obesity cardiometabolic A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders The obesity rate in the

Asia Pacific GLP-1 Receptor Agonist Market: Asia Pacific is registered the fastest growth rate during the forecasted period driven by Rising prevalence of diabetes and obesity, approvals for new indications or formulations, and increasing healthcare access in emerging markets

The GLP-1 based therapies were also not associated with a significant change in adiponectin levels in the blood with a mean difference in percent change from baseline between GLP-1 based therapies and controls of 53.63 [133.86, 26.61] % (P = 0.19

Yang, J

Who Should Use Hers and Hims GLP-1 Clinics

Hence, there is a critical need to enhance our understanding through pharmacological management, which unfortunately remains limited

It was added because rodents developed thyroid C-cell tumors in animal studies, and that raised enough concern to justify a strong warning label